Molecular Pharmacology (USA), Ltd. (MLPH)
OTCMKTS · Delayed Price · Currency is USD
0.0008
0.00 (0.00%)
At close: Mar 6, 2026

Molecular Pharmacology (USA) Company Description

Molecular Pharmacology (USA), Ltd., a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States.

The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain.

Its products are available in various dosage forms, formulations, line extensions, and package configurations.

The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe.

It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient.

The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.

Molecular Pharmacology (USA), Ltd.
Country United States
Industry Shell Companies
Sector Financials
Employees 1
CEO Jeffrey Edwards

Contact Details

Address:
Drug Discovery Centre
Perth, Washington 6007
Australia
Phone 61 8 9443 3011

Stock Details

Ticker Symbol MLPH
Exchange OTCMKTS
Fiscal Year July - June
Reporting Currency USD
ISIN Number US60852T1097
SIC Code 2834

Key Executives

Name Position
Jeffrey David Edwards Chief Executive Officer, President, Chief Financial Officer and Director